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A Major Histocompatibi l i ty Complex  Class II Restriction for 
BioBreeding/Worcester Diabetes- inducing T Cells 
By Karen E. Ellerman and Arthur A. Like 
From the Department of Pathology, University of Massachusetts Medical School, Worcester, 
Massachusetts 01655-0125 
Summary  
Inbred diabetes-prone (DP) BioBreeding/Worcester (BB/Wor) (P,.T1 u) rats develop spontane- 
ous autoimmune diabetes, which, like human insulin-dependent diabetes mellitus, is mediated 
by autoreactive T lymphocytes. Breeding studies have shown an absolute requirement for at 
least one copy of  the major histocompatibility complex (MHC) RT1 u haplotype for spontane- 
ous diabetes expression. Concanavalin A-activated spleen cells from acutely diabetic DP rats 
adoptively transfer diabetes only to recipients that express at least one RT1 u haplotype. To in- 
vestigate the basis for the MHC requirement in BB/Wor  autoimmunity, diabetes-inducing T 
cell lines were derived from the spleens of  acutely diabetic DP rats. Upon activation in vitro 
with islet cells, the T cell lines adoptively transfer insulitis and diabetes into young DP recipi- 
ents and non-diabetes-prone RT1 congenic rat strains that are class II u. Recipients that are 
tLT1 u at only the class I A or C locus, but not at the class II B /D  loci, do not develop diabetes 
after T cell transfer. The adoptive transfer of  diabetes by Concanavalin A-activated iabetic DP 
spleen cells also requires that donor and recipient share class II B /D  u gene products. Further- 
more, the adoptive transfer of diabetes into MHC class II u congenic rats is independent of  the 
class I haplotype; i.e., it occurs in the presence of class I A a C u or A u C a gene products. BB/  
Wor  T cells can be activated in vitro for the transfer of diabetes with islet cell antigens and class 
II-positive but not class IP-negative antigen-presenting cells. The inductive phase of  BB dia- 
betes is therefore MHC class II restricted, and this appears to operate at the level of  interaction 
between inducing T cells and class II u antigen-presenting cells. These results may explain the 
well-documented, but not yet understood, MHC class II genetic contribution to insulin-de- 
pendent diabetes mellitus pathogenesis, and they may facilitate the development of protocols 
designed to prevent diabetes onset in susceptible individuals. 
D iabetes-prone (DP) 1 BioBreeding/Worcester (BB/ Wor) rats develop spontaneous autoimmune diabetes, 
in which the frequency of insulin-dependent, ketosis-prone 
hyperglycemia s 80-95% in both sexes. BB diabetes is char- 
acterized morphologically by a [3 cell-specific mononuclear 
cell infiltrate (insulitis) within the pancreatic islets of Langer- 
hans. The autoimmune attack selectively destroys the insu- 
lin-producing [3 cells, with sparing of glucagon-, somatosta- 
tin-, and pancreatic polypeptide-synthesizing slet cells (1). 
These clinical features of BB diabetes are identical to those 
of human insulin-dependent diabetes mellitus (IDDM) (2). 
BB/Wor  rat diabetes is T cell dependent; the develop- 
ment of hyperglycemia is prevented by neonatal thymec- 
tomy (3) and in vivo treatment with mAbs directed against 
CD5 + (pan T) or CD8 + (cytotoxic) T cells (4). Spontane- 
1Abbreviations u ed in this paper: BB/Wor, BioBreeding/Worcester; CAS, 
Con A-activated Lewis rat splenocytes; DP, diabetes prone; DR, diabetes 
resistant; IDDM, insulin-dependent diabetes meUitus; NOD, nonobese 
diabetic; SEE, staphylococcal enterotoxin E.
ous BB diabetes is an MHC- l inked disease. Breeding stud- 
ies have shown an absolute requirement for at least one 
copy of  the MHC RT1 u haplotype for the appearance of  
spontaneous diabetes in crosses between BB and non-BB 
strains of  rat (5-7). Genetic susceptibility, however, has not 
been previously assigned to single genes of  the MHC,  nor 
have the immune effector mechanisms leading to [3 cell de- 
struction been identified as being class I -  or class I I - re-  
stricted events. 
BB/Wor  diabetes can be adoptively transferred with 
acutely diabetic DP spleen cells that have been activated in 
vitro with Con A, a polyclonal mitogen (8), or staphylo- 
coccal enterotoxin E (SEE; Toxin Technology, Sarasota, 
FL) (9), a T cell receptor V[3 family-specific stimulus (10). 
Adoptive transfer has been demonstrated using young DP 
(8), cyclophosphamide-treated histocompatible RT1 u non- 
BB (11) or athymic nude RT1 u rats (12) as recipients. 
Transfer studies using young DP recipients have implicated 
both the CD4 + (13) and CD8 + (14) T cell subsets as being 
necessary for adoptive transfer. Since DP recipients possess 
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an endogenous cohort of autoreactive CD4 + and CD8 + T 
cells, these studies do not permit a precise determination f 
the cell type required for initiating the diabetogenic pro- 
cess. Experiments designed to discriminate between induc- 
tive versus effector events and to map each arm of the dia- 
betogenic immune response to a specific MHC locus would 
require the use ofnon-BB,  non-diabetes-prone ILT1 u class 
I or class II congenic recipients in adoptive transfer studies. 
In non-BB P,.T1 u congenic recipients, one can measure de 
novo disease induction rather than the acceleration of a 
spontaneous disorder that would eventually occur in diabe- 
tes-prone BB recipients. 
To investigate the basis for the MHC requirement in BB 
autoimmune diabetes, diabetes-inducing T cell lines were 
generated from the spleens of acutely diabetic DP rats. The 
diabetes transfer capabilities of the T cell lines were tested 
in syngeneic and class I or class II congenic non-diabetes- 
prone recipients. The ability of class I or class II congenic 
APC to activate the T cells in vitro for the adoptive transfer 
of diabetes in vivo was also assessed. The results presented 
herein explain, at least in part, the MHC genetic ontribu- 
tion to IDDM pathogenesis in the rat and shed light on the 
pathogenesis of [3 cell destruction. 
Materials and Methods 
Animals. BB/Wor DP and BB/Wor diabetes-resistant (DR.) 
rats and inbred PVG.IL8, PVG.I~3, LEW1.AK2, and LEW1.WtL1 
rats were raised at the University of Massachusetts Medical Cen- 
ter (Worcester, MA) under viral antibody-free conditions. Viral 
antibody-free LEW1.AtL2 and LEW1.WIL1 breeding stock were 
obtained from the Central Institute for Laboratory Animal Breed- 
ing (Hannover, Germany). 
Islet Cell Preparation. Islets were isolated from 90-d DIL rats 
by the method ofGotoh et al. (15). Pancreatic tissue was digested 
with 4 mg/ml collagenase P (Boehringer Mannheim Corp., Indi- 
anapolis, IN) for 25 min at 37~ Islets were enriched on Histo- 
paque 1077 (Sigma Chemical Co., St. Louis, MO) (1,800 rpm, 
30 rain, 4~ and purified by handpicking under a microscope. 
Islets were dispersed in trypsin/EDTA {12 min at 37~ and im- 
mediately cryopreserved in 10% DMSO/45% ILPMI 1640/45% 
FCS. Freshly thawed islet cells were "/irradiated (3,000 IL) before 
use. To deplete residual islet-associated APC, freshly thawed islet 
cells at 106/ml were sonicated 2 • 20 s on ice with an ultrasoni- 
cator (Microson; Heat Systems Inc., Farmingdale, NY). 
Generation of T Cell Lines. Spleens were taken from acutely 
diabetic DP rats (duration of diabetes <5 d), processed into sin- 
gle-cell suspensions, allowed to adhere to plastic for 2 h at 37~ 
and plated at 6 • 106 nonadherent cells/ml in 1LPMI 1640, 2% 
autologous rat serum, and 2 ~zg/ml SEE at 37~ in 6.5% CO2. 
After 3 d, the activated blasts were purified on Histopaque 1077 
(2,000 rpm, 20 min, 22~ and plated at 105/ml in tLPMI 1640, 
10% heat-inactivated FCS (Hyclone Laboratories, Logan, UT), 
and 5% supematant from 48-h Con A-activated Lewis rat spleno- 
cytes (CAS). After two to three passages in CAS, the cells were 
restimulated for 3 d at 4 • 10S/ml with whole 3,000-R irradiated 
DR islet cells (freshly thawed after cryopreservation), 5% CAS, 
and 1.25 • 106/ml irradiated nonadherent DP spleen cells (3,000 
IL) in ILPMI 1640, 1% autologous rat serum. The ratio of islet 
cells to T cells was ,'~1:22. Antigen-activated blasts were again 
purified on Histopaque 1077 (2,000 rpm, 15 rain, 22~ plated 
at 105/ml in 10% CAS, and passaged several times before restimu- 
lation with antigen (islet cells or SEE) and APC. Culture medium 
consisted of ILPMI 1640, 1 mM sodium pyruvate, 2 mM 
glutamine, 10 mM Hepes, 5 • 10 -5 M 2-ME, and 1• antibi- 
otic/antimycotic (GIBCO BILL, Gaithersburg, MD). Before 
adoptive transfer, T cell lines were activated for 3 d with antigen 
and APC. Blast-transformed cells were harvested on Histopaque 
1077 and cultured for a further 2 d in 10% CAS. ILesting (un- 
stimulated) T cells were transferred after two passages in 10% 
CAS. 
Adoptive Transfer of T Cell Lines into DP Rats. T cells were in- 
jected intraperitoneally into 21-28-d female DP rats, which were 
monitored for 21 d after transfer for the development of glycos- 
uria (TesTape; Eli Lilly and Co., Indianapolis, IN) and hypergly- 
cemia (blood glucose ->13.8 retool/liter; Beckman Glucose Ana- 
lyzer II; Beckman Instruments, Inc., Fullerton, CA). The mean 
age at onset of spontaneous diabetes in the University of Massa- 
chusetts Medical Center DP colony is 75 d for females with an 
incidence of 0.04% at 45 d of age. Hyperglycemia detected before 
45 d of age was considered tobe the result of the injected T cells. 
Diabetic rats were killed on the day of detection, and nondiabetic 
rats at 21 d after transfer. 
Adoptive Transfer of T Cell Lines into RTI" Congenic Rats. Islet 
cell-activated T cells were injected intraperitoneally into 21-30-d 
male and female congenic rats treated 24 h earlier with cyclo- 
phosphamide (Cytoxan; Mead Johnson Laboratories, Princeton, 
NJ), 180 mg/kg body weight i.p. ILats were monitored for 21 d 
for the development of glycosuria nd hyperglycemia (blood glu- 
cose -->13.8 mmol/liter). 
Con A Activation of Acutely Diabetic DP Spleen Cells. Spleens 
were taken from acutely diabetic DP rats (duration of disease <5 
d), processed into single-cell suspensions, and cultured at 5 • 106 
ceUs/ml in RPMI 1640, 2 mM glutamine, 10 mM Hepes, 5 X 
10 -5 M 2-ME, 5% FCS, and 4 I.Lg/ml Con A (ICN Biomedicals, 
Inc., Costa Mesa, CA) for 3 d at 37~ 6.5% CO 2. Activated cells 
were washed four times in ILPMI 1640 before injection. One 
spleen equivalent of Con A-activated cells was injected intraperi- 
toneally into recipient rats. 
Morphologic Studies. Pancreata and thyroids were fixed in 
Bouin's solution and embedded in paraffin. Hematoxylin and 
eosin stained sections were examined for the presence of insulitis 
and thyroiditis. Selected sections were immunostained for insulin 
and glucagon (16) to evaluate the selective destruction ofpancre- 
atic oL and [3 cells. 
mAbs. OX-8 (anti-CD8) (17) and W3/25 (18, 19) (anti-CD4) 
mAbs were produced by hybridoma cell lines from Dr. A. Will- 
iams and Dr. D. Mason (Oxford University, Oxford, UK). The 
3.2.3 hybridoma was obtained from J. C. Hiserodt. The 3.2.3 
mAb recognizes rat NK cells and selectively depletes NK cells in 
vivo (20, 21). Undiluted tissue culture supernatants were used for 
flow cytometry as previously described (4). 
Results 
Generation and Characterization of BB /Wor Diabetes-induc- 
ing T Cell Lines. BB/Wor  autoimmune diabetes can be 
adoptively transferred into syngeneic recipients with acutely 
diabetic DP spleen cells that have been activated in vitro by 
SEE, a TC1L V[3 family-specific stimulus (9). T cell lines 
were generated from the spleens of acutely diabetic DP rats 
by first culturing them in vitro with SEE. After 3 d, SEE- 
reactive lymphoblasts ("~9% of input spleen cells) were en- 
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riched on density gradients and recultured in CAS as a 
source o fT  cell growth factors. At the second round of  an- 
tigen-specific selection, T cells were stimulated with whole 
BB/Wor  islet cells and APC. Islet cell-reactive T lympho- 
blasts were density gradient purified and passaged further in 
CAS. At the third cycle of  antigen activation, T cells lines 
were restimulated with either SEE and APC or with islet 
cells and APC. This protocol generates a population of  T 
cells with potent diabetes transfer activity. A single intra- 
peritoneal injection of  12-34 • 106 T cells adoptively 
transferred iabetes into 21-28-d-old DP recipients in as 
few as 5 d after cell injection (Table 1), with a mean time 
to hyperglycemia of  7.9 d (n = 48). DP rats also develop 
spontaneous thyroiditis, although at a low and variable in- 
cidence (22). Diabetic recipients of  T cell lines, however, 
did not develop thyroiditis (n = 48). Hyperglycemia was 
always accompanied by a 13 cell-destructive insulitis. 
Only antigen-activated T cells transfer disease; unstimu- 
lated (resting) T cells transferred >5 d after antigen activa- 
tion (with islet cells or SEE) did not induce adoptive diabe- 
tes (Table 1, line 4) or insulitis. By single-color flow 
cytometry, the cell lines were comprised (at all time points 
tested) of  70-90% CD4 + and 10-30% CD8 + T cells (data 
not shown). Although DP rats have low, barely measurable 
levels of  CD8+/CD5 + CTLs and increased numbers of  
CD8+/CD5- /3 .2 .3  + NK cells (23, 24), the T cell lines did 
not contain 3.2.3 + NK cells at any time. The cell lines pro- 
liferate in vitro in response to both islet cells and SEE (data 
not shown). One cell line (A91-1), also derived from 
acutely diabetic DP spleens, was initially selected and then 
repetitively stimulated in vitro with whole islet cells and 
APC, but it did not transfer diabetes or insulitis into any of  
28 DP recipients (21-25 d old) given 19-57 X 106 T cells 
(data not shown). The initial in vitro activation step with 
SEE appears to select for T cells with both islet cell reactiv- 
ity and diabetes transfer capabilities. 
Adoptive Transfer of T Cell Line-mediated Diabetes is MHC 
Class II" Restricted and Independent of Class I Haplotype. To 
exclude the possibility that the T cell lines were simply ac- 
celerating or costimulating an endogenous immune process 
genetically present in DP recipients, T cell lines were trans- 
ferred into ILT1 congenic non-BB strains of  rat. These 
congenics contain non-BB RT1 u genes, in different allelic 
combinations on the genetic background of  parental Lewis 
(RT11) and PVG (ILT1 c) strains. Neither the I~T1 u con- 
genics nor their parental strains spontaneously develop in- 
sulitis or diabetes. To prepare congenic rats for BB/Wor  T 
cell injections, recipients were treated with cyclophospha- 
mide 24 h before transfer. Cyclophosphamide pletes T 
cells and enables RT1 congenic rats to accept he BB/Wor  
T cells, with which they share only partial genetic identity 
(11). Cyclophosphamide alone does not induce diabetes or 
insulitis in RT1 congenic rats (see Table 3). 
Islet cell-activated T cell lines injected into PVG.R8 rats 
induced diabetes and insulitis in 14 out of  17 recipients, 
with a mean time to hyperglycemia of 7.4 d (Tables 2 and 
3). Pancreatic tissue sections taken from diabetic and con- 
trol cyclophosphamide-treated PVG.R8 rats were immun- 
ostained for the localization of  islet cell peptide hormones. 
Islets of  Langerhans from diabetic rats exhibited destructive 
lymphocytic insulitis with depletion of  insulin-producing 13
cells and sparing of  glucagon-producing ot cells (Fig. 1 C 
and D) and somatostatin-producing 5 cells (data not shown). 
Cyclophosphamide-treated rats revealed no insulitis and 
had normal numbers and distributions of  or, [5 (Fig. 1, A 
and B), and 8 cells. Islet cell-activated T cells also trans- 
ferred diabetes and insulitis into 9 out of  10 LEW1.WR1 rats 
(Table 3), with a mean time to hyperglycemia of 9.7 d and 
a mean blood glucose of  20.4 retool/liter. Thus, BB/Wor  
islet cell-activated T cell lines have an in vivo specificity for 
insulin-producing 13 cells, even when transferred into a 
non-BB genetic environment. 
When islet cell-activated T cells were transferred into 
PVG.R23 recipients, none of the rats developed insulitis or 
diabetes (Table 3). T cells from the lines used in these ex- 
periments (at the same or a later passage) transferred iabe- 
Table 1. BB/Wor Diabetes-inducing T Cell Lines 
Incidence Mean time Mean blood 
Cell line of diabetes Stimulus Cell No. to diabetes glucose 
>( 106 d mmol/liter 
BF-1 6/6 Islet cells 16-20 7 26.4 
BF-1 3/3 SEE 32 5 25.0 
BB-3 4/4 Islet cells 19 6 19.8 
BB-3 0/4 None 22 - -  - -  
BB-3 2/2 Islet cells 12 8 15.7 
BB-5 3/3 SEE 34 12 28.9 
J193 2/3 Islet cells 17 7 27.9 
T cell lines were activated for 3 d with islet cells/APC or SEE/APC as described in Materials and Methods. Blast-transformed c lls were harvested 
on Histopaque 1077 and cultured for a further 2 d in 10% CAS. Resting T cells (no stimulus) were transferred after 2 passages in CAS. T cells were 
injected intraperitoneally into 21-28 d female DP rates. Recipients were monitored for 21 d for the development ofhyperglycemia (blood glucose 
>-13.8 retool/liter). A total of 45 out of 48 DP rats injected with T cell lines developed diabetes, with a mean time to hyperglycemia of 7.9 d. 
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Table 2. Adoptive Transfer of Diabetes into PVG.R8 Rats by 
Islet Cell-activated BB/Wor T Cell Lines 
Incidence Mean time Mean blood 
Cell line Cell No. of diabetes to diabetes glucose 
X I06 d mmol/liter 
Ju92 31 3/4 7 23.8 
BB-5 39 6/6 7.5 25.2 
092 16 3/4 8 17.9 
092 29 2/3 7 24.6 
T cell lines were activated for 3 d with islet cells and APC as described 
in Materials and Methods. Blast-transformed ceils were harvested on 
Histopaque 1077 and cultured for a further 2 d in 10% CAS. T cells 
were injected intraperitoneaUy into 21-30-d female PVG.R8 rats 
treated 24 h earlier with cyclophosphamide, 180 mg/kg body weight. 
None of eight female PVG.R8 rats given 180 mg/kg cyclophospha- 
mide alone developed iabetes or insulitis. All rats were monitored for 
21 d for the development ofglycosuria and hyperglycemia (blood glu- 
cose -----13.8 mmol/liter). 
tes into 9 out o f  10 DP recipients and six out of  six 
PVG.R8 rats, conf irming their in vivo diabetogenicity. Is- 
let cell-activated T cells injected into LEW1.AR2 rats did 
not induce diabetes or insulitis in seven recipients (Table 
3), even though the same line concurrently transferred ia- 
betes into two out of  two rats given 18 X 106 T cells, with 
a mean time to hyperglycemia of  8 d (data not shown). 
There were no signs of  GVHD in PVG.R23 or LEW1.AR2 
recipients. 
The combined data from Tables 2 and 3 demonstrate 
that donor  and recipient must share class II RT1  ~ gene 
products for the successful transfer of  BB/Wor  diabetes. 
R.T1 ~ congenicity at only the class I RT1A or RT IC  locus 
is not sufficient for T cel l -mediated transfer of  diabetes. O f  
importance is the observation that the adoptive transfer o f  
auto immune diabetes into class IP  congenic rats is inde- 
pendent  of  the class I haplotype; i.e., diabetes transfer oc- 
curs in the presence of  class I A a C ~ (PVG.R8) or A u C ~ 
(LEW1.WR1)  gene products. 
Adoptive Transfer of Diabetes by Con A-activated Acutely 
Diabetic DP Spleen Cells Also Requires that Donor and Recipi- 
ent Share Class II u Gene Products. To confirm the in vivo 
MHC restriction pattern obtained with islet cell-activated 
T cell lines, Con  A-activated acutely diabetic DP spleen 
cells were also injected into cyclophosphamide-treated RT1
congenic rats. One  spleen equivalent o f  Con  A-activated 
cells transferred iabetes and insulitis into PVG.R8 and 
LEW1.WR1 but not PVG.R23 and LEW1.AR2 rats (Ta- 
ble 4). 13 out of  14 LEW1.AR2 recipients developed ful- 
minant  GVHD (manifested by wasting, anemia, and mas- 
sive splenomegaly) 10 d after transfer. Two out of  three DP 
rats concurrently receiving the same Con A-activated spleen 
cells developed diabetes at 10-11 d after transfer. Thus, 
cells with diabetogenic potential survived in LEW1.AR2 
recipients, but without inducing hyperglycemia or insulitis. 
As assessed by adoptive transfer, the cognitive or induc-  
tive phase of  BB diabetes is MHC class II u restricted and 
can proceed in the presence of  either class I A ~ or C ~ gene 
products. Thus, the induct ion of  transferred iabetes is de- 
pendent  first upon CD4 + T cell recognit ion of  f3 cell au- 
toantigen in the context of  class II u in recipient arget issue 
(islet of  Langerhans). These experiments do not, however, 
rule out a role for CD8 + CTL  in the auto immune attack 
leading to [3 cell destruction. 
Class IP Restriction of BB Diabetes Operates at the Level of 
Interaction between Inducing T Cells and APC. To examine 
the APC as a potential locus for the class II u restriction, BB 
T cell lines were activated in parallel with sonicated BB is- 
let cells and BB or RT1  congenic APC (irradiated spleen 
Table 3. Adoptive Transfer of Diabetes into MHC Congenic Rat 
Strains by Islet Cell-activated BB/Wor T Cell Lines 
RT1 Incidence of Incidence of 
Strain haplotype Cell No. diabetes insulitis 
>( 106 
PVG.R8 A~B/D"C u 16-39 14/17 14/17 
PVG.R8 AaB/DUC u 0 0/8 0/8 
PVG.R23 AuB/D~C ~vl 27-36 0/14 0/14 
PVG.R23 AuB/DaCavl 0 0/11 0/11 
LEW1.AR2 A~B/DaC u 36 0/7 0/7 
LEW1.AR2 A~B/DaC u 0 0/10 0/10 
LEW1.WR1 AuB/D~C~ 28 9/10 9/10 
LEW1,WR1 AuB/D~Ca 0 0/7 0/7 
21-30-d-old male and female RT1 congenic rats received cyclophos- 
phamide, 180 mg/kg body weight intraperitoneally, 24 h before cell 
transfer. Control rats received cyclophosphamide alone. Rats were 
monitored for 21 d for glycosuria nd hyperglycemia (blood glucose 
-> 13.8 mmol/liter). 
Table 4. Adoptive Transfer of Diabetes into MHC Congenic Rat 
Strains by Con A-activated Spleen Cells from Acutely Diabetic 
Diabetes-prone BB/Wor Rats 
RT1 
Strain haplotype Diabetes Insulitis 
PVG.R8 AaB/DuCu 19/23 21/23 
PVG.R23 AuB/DaC "vl 0/17 0/17 
LEW 1 .AR2 A~B/D~C u 0/14 0/11 
LEW1 .WR1 AuB/DuC~ 5/5 5/5 
BB/Wor DP AuB/DuC u 24/27 25/27 
Recipients were 21-30-d-old rats of both sexes. Each rat received one 
spleen equivalent of Con A-activated acutely diabetic DP spleen cells 
intraperitoneally or intravenously. Congenic rats received cyclophos- 
phamide, 150-I80 mg/kg body weight i.p., 24 h before spleen cell in- 
jections. For each experiment, cells were concurrently transferred into 
both congenic and BB rats. Recipients were monitored for 3 wk (BB 
rats) or 4 wk (congenic rats) for the development of hyperglycemia 
(blood glucose -> 13.8 mmol/liter). 
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Figure 1. Photomicrographs show adjacent pancreatic slet sections taken from PVG.I~8 rats treated with cyclophosphanfide alone (A, B) or cyclo- 
phosphamide followed 24 h later by an injection of islet cell-activated BB/Wor T cells (C, D). Tissues were fixed in Bouin's solution, and an immuno- 
peroxidase t chnique was used for identification of insulin (A, C) and glucagon (B, D). The islets of cyclophosphamide control (A,/3) reveal no evidence 
ofinsulitis. Insulin-positive [3 cells (A) and surrounding glucagon-positive ix cells (/3) are normal in appearance. The islets of the diabetic rat reveal an in- 
traislet mononuclear cell infiltrate with almost complete destruction of the pancreatic ~3 cells (C). Peripheral glucagon-positive ix cells (D) are preserved in
the diabetic PBV.R8 rats. A and B, • C and D, • 
cells). The sonication step was added to deplete the isl t 
cells of intact class II § APCs of BB origin, as such cells are a 
normal component of the islets of Langerhans. After activa- 
tion, equal numbers of T cells were injected into 21-25-d 
DP recipients, which were monitored for hyperglycemia 
for 15 d after cell injection. BB T cells activated in vitro 
with islet cell antigens and BB, PVG.R8 (B/D"), or 
LEW1.WR1 (B/D") APC, but not PVG.R23 (B/D a) or 
LEW1.AP,.2 (B/D a) APC, adoptively transferred iabetes 
(Table 5). Thus, BB diabetes-inducing T cells are class IP 
restricted both in vivo and in vitro. The class II restriction 
appears to operate at the level of the interaction between 
inducing T cells and class II u APC. 
Discussion 
BB autoimmune diabetes i an MHC-linked disease with 
a requirement for both CD4 + (13) and CD8 + (4, 14) T 
cells. To investigate the basis for the MHC requirement, 
diabetes-inducing T cell lines were generated from the 
spleens of acutely diabetic DP rats. When activated in vitro 
with whole islet cells and APC, the T cell lines have potent 
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diabetes transfer activity, wherein a single injection of T 
cells adoptively transferred hyperglycemia nto 21-28-d- 
old DP recipients in as few as 5 d after injection. Hypergly- 
cemia was always accompanied by a [3 cell-destructive in- 
sulitis with sparing of the glucagon- and somatostatin-se- 
creting islet cells. Although DP rats may also develop 
spontaneous thyroiditis (22), diabetic recipients of T cell 
lines never manifested any signs of intrathyroid lympho- 
cytic infiltrates. Interestingly, the T cell lines can also be ac- 
tivated for diabetes transfer with the superantigen, SEE. 
The ability of a superantigen to activate diabetes-inducing 
T cells is reminiscent of a recent report suggesting a role for 
superantigen i  human IDDM etiology (25). 
To determine which type o fT  cell initiates the develop- 
ment of diabetes, BB/Wor T cell lines were injected into 
non-diabetes-prone RT1 u class I or class II congenic recip- 
ients. Upon islet cell activation in vitro, the T cell lines 
rapidly transferred insulitis and diabetes into class IP con- 
genic rats. Recipients that are RT1 u at only the class I A or 
C locus, but not at the class II B/D loci, did not develop 
diabetes after T cell transfer. The adoptive transfer of dia- 
Table 5. BB/Wor Diabetes-inducing T Cells Require Activation 
with MHC Class II"-positive APC and Islet Cell Antigens for 
Disease Transfer 
Experiment Source Class II Incidence Mean time 
No. of APC loci of diabetes to diabetes 
d 
1 BB/Wor B/D u 7/8 11 
PVG.R.23 B/D a 0/8 - -  
2 BB/Wor B/D u 6/7 9 
LEW1.WR1 B/D u 4/5 10 
3 BB/Wor B/D u 7/8 9 
PVG.R.8 B/D u 8/9 9 
4 PVG.P,.8 B/D u 1/2 11 
LEW1.AI<2 B/D ~ 0/3 - -  
5 BB/Wor B/D u 4/4 12 
LEW1.AP,2 B/D ~ 0/2 - -  
BB/Wor T cells (4 • 10S/ml) were activated in parallel with DP or 
RT1 congenic 3,000-R spleen cells (2 • 106/ml), 5% FCS, 5% CAS, 
and sonicated BB islet cells. The sonicates were always checked micro- 
scopically for the absence of whole cells. Islet cell sonicates were used at 
a ratio of 1 cell equivalent per 21 T cells. After 3 d, blasts were har- 
vested on Histopaque 1077 and cultured for 2 d in 10% CAS. Equal 
numbers of T cells (usually 25 • 106) were then injected intraperito- 
neally into 21-25-d female DP rats, which were monitored for 15 d for 
the development of glycosuria nd hyperglycemia (blood glucose 
--- 13.8 mmol/liter). 
betes by Con A-activated, acutely diabetic DP spleen cells 
also requires that donor and recipient share class II B /D  u 
gene products. Therefore, the induction of  BB diabetes is 
restricted by class II u gene products and is CD4 + T cell me- 
diated. Of  importance is the fact that the adoptive transfer 
of  diabetes into class IP congenic rats is independent of  the 
class I haplotype; i.e., it occurred in the presence of  class I 
A a C u (PVG.RS) or A u C a (LEW1.W1L1) gene products. In 
contrast, the adoptive transfer of  antiviral cytotoxic CD8 + 
T cell effector activity is restricted by recipient class I, but 
not class II, genes (26). 
These data are surprising, because, in the rat, the insulin- 
producing 13 cell targets do not express detectable MHC 
class II gene products in vivo (27-29), even during the 
course of  spontaneous BB/Wor  insulitis and diabetes (30). 
BB rat 13 cells do, however, express class I products in vivo, 
with class I hyperexpression a d infiltrating CD8 + T cells 
being invariant concomitants of the autoimmune attack 
(24, 28, 31). It is likely that 13 cells in situ shed or secrete a 
protein that is taken up by class II + intraislet APC, which 
process and then present antigen to 13 ceil peptide-specific 
CD4 + T cells in a class II-restricted manner. The activated 
CD4 + T cells would, in turn, activate 13 cell peptide-spe- 
cific CD8 + T cells, which would serve as the final effectors 
of  [~ cell cytolysis. CD8 + T cells are known to be critically 
important in BB diabetes. Ant i -CD8 mAb treatment re- 
moves CD8 + CTL and decreases the incidence of  sponta- 
neous BB diabetes (4, 24). In vitro-activated acutely dia- 
betic BB spleen cells, when depleted of  CD8 + cells, do not 
adoptively transfer disease into CD8-depleted DP recipi- 
ents (14). CD8+/3.2.3 +NK cells are not the final effectors 
of 13 cell cytolysis, because 3.2.3 mAb treatment of  DP rats 
removes NK cells but does not reduce the frequency of  BB 
diabetes (24). 
Although the induction of  BB diabetes is clearly an 
MHC class II-restricted CD4 + T cell-mediated event, the 
data do not rule out a role for CD8 + CTL as the final el- 
lectors of  13 cell destruction. In the case of  the diabetes-in- 
ducing T cell lines described above, it has not been shown 
that the transferred CD8 + T cells actually play a role in 
adoptive diabetes. It is possible that the CD4 + T cells 
(which make up 70-90% of the diabetes-inducing T cell 
lines) are recruiting 13 cell---specific CD8 + CTL from within 
the recipient T cell compartment. Alternatively, the trans- 
ferred CD4 + T cells may be homing to the islets of  Langer- 
hans and inducing the production of  inflammatory cyto- 
kines in situ that ultimately lead to [3 cell cytosis (32). A 
formal demonstration of a role for CD8 + CTL in BB dia- 
betes would depend upon the ability of  islet cell-activated 
CD8 + T ceils to adoptively transfer insulitis and hypergly- 
cemia into class I u congenic recipients, irrespective of  the 
animals' class II haplotype. Finally, i fCD8 + CTL are the fi- 
nal effectors of  13 cell cytolysis, then the data presented 
above suggest that they can recognize 13 cell autoantigen i the 
context of  either class I A u (LEW1.WR1) or C u (PVG.IL8) 
gene products. 
In the nonobese diabetic (NOD) mouse model of  
IDDM, both CD4 + and CD8 + spleen cell populations are 
also required for the transfer of diabetes into young NOD 
(33-35) or NOD-sc id/sc id  recipients (36). However,  the 
matter has not been further clarified by transferring spleen 
cells into other inbred strains of  mice that are class I (H- 
2K~D b) or class II (NOR/L t  [37], B10.H-2g 7 [38]) con- 
genic with NOD mice. Diabetes-accelerating CD4 + T cell 
clones have been described in the NOD mouse (39), but 
their ability to induce (as opposed to accelerate) diabetes in 
non-NOD MHC class II congenic recipients has not been 
reported. Furthermore, the acceleration of  diabetes in 
NOD mice given CD4 + T cell clones is effective only if 
the recipients are <19 d of  age (40). In contrast, BB T cells 
efficiently transfer diabetes into 21-30-d-old BB or class II L' 
congenic recipients. 
The MHC contains the predominant genetic susceptibil- 
ity factors for IDDM in humans (41, 42), the BB rat (7), 
and the NOD mouse (43, 44). In particular, MHC class II 
genes are associated with disease susceptibility in all three 
species (45-47). The manner in which the products of  the 
IDDM-associated MHC genes influence the pathogenesis 
of diabetes is still unknown. The mechanism could be ei- 
ther at the level of  thymic T cell selection or during pe- 
ripheral immune response activation, both of  which re- 
quire appropriate peptide presentation by MHC molecules. 
Our  data indicate that, in the BB rat, the MHC class II ge- 
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netic contribution to IDDM pathogenesis may be explained 
by binding of  [3 cell peptide to permissive class II" mole- 
cules, resulting in the activation of  diabetes-inducing T 
cells. Specifically, BB T cells can be activated in vitro for 
the transfer of  diabetes with islet cell antigens and class II u- 
positive, but not class IIU-negative, APC (Table 5). The 
MHC class II restriction of  BB diabetes thus operates at the 
level of  interaction between inducing T cells and class II u 
APC. These data lend support o the peptide affinity model 
for the class II genetic ontribution to IDDM susceptibility: 
Susceptibility is caused by peptide presentation by a class II 
gene product that binds diabetogenic peptide, resulting in 
the activation of  [3 cell-specific autoreactive T cells (48). 
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